Compare ATXG & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATXG | REVB |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | China | United States |
| Employees | N/A | 9 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | 2015 | N/A |
| Metric | ATXG | REVB |
|---|---|---|
| Price | $3.91 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7K | ★ 37.4K |
| Earning Date | 02-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.47 |
| 52 Week High | $7.94 | $2.93 |
| Indicator | ATXG | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 56.00 |
| Support Level | $0.32 | $0.95 |
| Resistance Level | $4.14 | $1.21 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.89 | 67.94 |
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services and Consulting. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.